Resistance to endocrine therapy in breast cancer is associated with the activation of the phosphatidylinositol 3-kinase (PI3K)–Akt-mammalian target of rapamycin (mTOR) intracellular signaling pathway. This evidence concerns the gene MTOR and breast cancer.